Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category

Angelo Navas, Joshua Noone, Nathan Laney, Sunny Sheth, Xi Tan, Yuanjie Liang, Paloma Munoz, Caroline Swift · 2026

Read Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category by Angelo Navas, Joshua Noone, Nathan Laney, Sunny Sheth, Xi Tan, Yuanjie Liang, Paloma Munoz, Caroline Swift (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13253911.txt.

Description

Angelo Navas and co-authors re-analyze, in a 2026 paper, a major diabetes trial to ask whether losing more weight on the drug meant fewer heart events. The drug, semaglutide, lowers blood sugar and trims weight. Its heart protection is proven, but the weight link was unclear.

The original trial randomized people with type 2 diabetes against placebo. This later analysis groups the 1,479 drug-arm participants by how much weight they lost. It then compares rates of heart attack, stroke, and cardiovascular death across those groups. If benefit tracks weight, dosing and support could aim at the scale. If not, the drug protects the heart by other routes, and weight is a side story.

Catalog record

CREATORAngelo Navas, Joshua Noone, Nathan Laney, Sunny Sheth, Xi Tan, Yuanjie Liang, Paloma Munoz, Caroline Swift
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13253911

Browse the full library · About the Tower of Babel